Overview and Scope
Herpangina treatment refers to a treatment of viral illness that usually affects youngsters, creating painful sores or ulcers on the tonsils and back of the throat. The treatment is used for managing symptoms and supporting the body’s natural healing process, as herpangina is a viral infection that typically resolves on its own without specific antiviral medications.
Sizing and Forecast
The herpangina treatment market size has grown strongly in recent years. It will grow from $1.76 billion in 2023 to $1.88 billion in 2024 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to viral outbreaks and prevalence, pediatric population growth, healthcare infrastructure development, public health awareness programs, clinical research and treatment advancements.
The herpangina treatment market size is expected to see strong growth in the next few years. It will grow to $2.47 billion in 2028 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to emerging viral strains, increasing focus on pediatric health, international health regulations, technological innovations in diagnostics, healthcare access improvements. Major trends in the forecast period include development of topical therapies for oral lesions, integration of telemedicine for diagnosis and consultation, enhanced patient education and awareness programs, collaborations for clinical trials and research, global health preparedness initiatives.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/herpangina-treatment-global-market-report
Segmentation & Regional Insights
The herpangina treatment market covered in this report is segmented –
1) By Treatment: Topical Anesthetics, Ibuprofen Or Acetaminophen, Other Treatments
2) By Virus: Coxsackie Virus A, Coxsackie Virus B, Enterovirus 71, Echovirus
3) By Symptoms: High Fever, Sore Throat, Blisters Or Ulcers In The Throat Mouth, Difficulty Swallowing, Loss Of Appetite, Neck Pain, Swollen Lymph Glands, and Headache
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users
North America was the largest region in the global herpangina treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the herpangina treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10855&type=smp
Major Driver Impacting Market Growth
The rise in prevalence of the herpangina is expected to propel the growth of the herpangina treatment market going forward. Herpangina is a viral illness that usually affects youngsters, creating painful sores or ulcers on the tonsils and back of the throat caused by coxsackievirus and enteroviruses. Herpangina therapy helps to reduce the severity of herpangina symptoms such as blisters, high fever, discomfort in the mouth or throat, drooling, and loss of appetite. For instance, in September 2022, according to the National Library of Medicine, a US-based biomedical library operated by the federal government stated that in China, the incidence of Coxsackievirus (Cox A16) cases increased to 1.09 cases (1/100,000) in 2021 compared to 2020. Further, the incidence of other enterovirus cases increased to 4.73 cases (1/100,000) in 2021 from 4.46 cases (1/100,000) in 2020. Therefore, the increasing incidence of herpangina is driving the growth of the herpangina treatment market.
Key Industry Players
Major companies operating in the herpangina treatment market report are Gilead Sciences Inc., Johnson and Johnson Services Inc., Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Vertex Pharmaceuticals Incorporated, Sanofi S.A, Novartis AG, Mitsubishi Tanabe Pharma Corporation, F. Hoffmann-La Roche AG, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, AstraZeneca plc, Bausch Health Companies Inc., Mylan N.V., GlaxosmithKline plc, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Cadila Healthcare Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Alkem Laboratories Ltd., Alembic Pharmaceuticals Ltd., Hetero Drugs Limited, Macleods Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Jubilant Life Sciences Ltd.
The herpangina treatment market report table of contents includes:
1. Executive Summary
- Market Characteristics
- Market Trends And Strategies
- Impact Of COVID-19
- Market Size And Growth
- Segmentation
- Regional And Country Analysis
………
- Competitive Landscape And Company Profiles
- Key Mergers And Acquisitions
- Future Outlook and Potential Analysis
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
